Repligen SEC Filings

Repligen Corporation reported that one of its directors exercised a stock option for common shares. On 12/16/2025, the director acquired 3,366 shares of common stock through an option exercise at a price of $26.12 per share, increasing the director’s direct beneficial ownership to 36,622 common shares after the transaction. The related stock option, which is fully vested and exercisable, covers 3,366 shares of common stock and carries an exercise price of $26.12 with an expiration date of May 11, 2026.

A director of Repligen Corporation reported an insider transfer of 2,000 shares of Repligen common stock on 12/04/2025. After this transaction, the reporting person beneficially owns 98,959 shares of common stock in direct form. The filing describes the move as a transfer of shares in which the reporting person is a joint tenant with right of survivorship, indicating a change in how the shares are held rather than a typical market sale.

Repligen Corporation (RGEN) reported an insider stock sale by its Chief Executive Officer, who is also a director. On 11/25/2025, the executive sold 7,041 shares of common stock at a price of $170 per share, as shown in a Form 4 filing. After this transaction, the executive directly held 35,898 shares of Repligen common stock.

The sale was carried out under a pre-arranged Rule 10b5-1 trading plan that was adopted on December 12, 2024, which is designed to allow insiders to sell shares according to a set schedule.

Repligen Corporation's Chief Operating Officer reported a stock sale in a Form 4. On 11/18/2025, the officer sold 2,191 shares of Repligen common stock in an open market transaction coded "S" (sale). The weighted average sale price was $151.21 per share, with individual trades executed between $151.21 and $151.62.

After this transaction, the officer directly beneficially owns 21,520 shares of Repligen common stock. The filing notes that detailed trade breakdowns by price within the range are available upon request from the company, its security holders, or the SEC staff.

Repligen Corporation director reported several transactions in company stock. On 11/13/2025, the director sold multiple blocks of common stock in open-market transactions at weighted average prices ranging from $151.01 to $157.11, each sale covering different share amounts. After these sales, the director beneficially owned 80,743 shares of Repligen common stock in direct form. The director also exercised a stock option for 2,952 shares at an exercise price of $33.87, which increased directly held shares while reducing the option position.

Repligen (RGEN) reported an insider transaction by a director on 11/12/2025. The director exercised 25,000 stock options at $33.87 and, on the same day, sold 25,000 common shares in multiple trades under a Rule 10b5-1 plan adopted on December 9, 2024. Sale prices were reported as weighted averages ranging from $154.92 to $158.51.

Following these transactions, the director directly owned 100,743 shares. The option reported expires on 03/01/2028, with 157,344 derivative securities beneficially owned after the transactions, and remaining tranches vesting 28,777 on 03/01/2026 and 28,778 on 03/01/2027.

Repligen Corporation reported Q3 2025 results with total revenue of $188.8 million and net income of $14.9 million, a turnaround from a $0.7 million loss a year ago. For the first nine months of 2025, revenue reached $540.3 million with net income of $35.6 million.

Cash and cash equivalents were $748.7 million, supporting a strong balance sheet with total assets of $2.92 billion. The company closed the 908 Devices bioprocessing analytics portfolio acquisition for $69.9 million in cash, recording provisional goodwill of $50.1 million and incurring $10.5 million in transaction and integration costs year to date. Contingent consideration fell to $7.6 million, producing gains of $4.1 million in Q3 and $12.1 million year to date.

The restructuring plan was completed in Q2 2025, with $4.1 million in related charges in the first nine months of 2025. The 1.00% Convertible Senior Notes due 2028 had a $537.9 million carrying amount and were not convertible for Q4 2025 under the indenture’s trading condition. Shares outstanding were 56,290,749 as of October 31, 2025.

Repligen Corporation filed an 8-K stating it announced financial results for the third quarter ended September 30, 2025. The company furnished the full text of the announcement as Exhibit 99.1, a press release dated October 28, 2025.

The information provided under Item 2.02 is furnished and is not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference, except as expressly set forth by specific reference.

Repligen Corporation reporting person Olivier Loeillot, who is listed as both a Director and the Chief Executive Officer, recorded a sale of common stock on 10/02/2025. The filing shows 1,248 shares were disposed of at a price of $145.23 per share, with 42,939 shares remaining beneficially owned after the transaction. The reported sale represents shares withheld by the issuer to satisfy tax withholding obligations arising from the release of restricted stock units, not an open-market purchase or voluntary sale. The Form 4 was signed on 10/06/2025 by an attorney-in-fact on behalf of the reporting person.